Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Acquired by Virtu Financial LLC

Virtu Financial LLC grew its holdings in Seres Therapeutics, Inc. (NASDAQ:MCRB) by 44.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 58,791 shares of the biotechnology company’s stock after purchasing an additional 18,191 shares during the quarter. Virtu Financial LLC’s holdings in Seres Therapeutics were worth $56,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in MCRB. Vontobel Holding Ltd. purchased a new stake in Seres Therapeutics during the 3rd quarter worth about $374,000. Geode Capital Management LLC grew its position in shares of Seres Therapeutics by 22.5% during the third quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock worth $1,314,000 after buying an additional 255,014 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Seres Therapeutics by 42.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock worth $708,000 after buying an additional 222,771 shares in the last quarter. FMR LLC increased its stake in shares of Seres Therapeutics by 0.6% during the third quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock worth $21,625,000 after buying an additional 140,096 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Seres Therapeutics in the second quarter valued at approximately $92,000. Institutional investors and hedge funds own 59.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on MCRB shares. Chardan Capital reiterated a “buy” rating and set a $1.25 price target on shares of Seres Therapeutics in a report on Wednesday, November 13th. StockNews.com downgraded shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 27th. Canaccord Genuity Group reissued a “buy” rating and issued a $10.00 target price on shares of Seres Therapeutics in a report on Thursday, November 14th. Finally, JPMorgan Chase & Co. downgraded Seres Therapeutics from a “neutral” rating to an “underweight” rating in a report on Thursday, October 24th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $5.08.

Seres Therapeutics Trading Down 0.6 %

MCRB stock opened at $0.92 on Friday. The stock has a market cap of $156.31 million, a P/E ratio of -3.98 and a beta of 2.07. Seres Therapeutics, Inc. has a twelve month low of $0.54 and a twelve month high of $2.05. The company’s 50 day moving average is $0.80 and its two-hundred day moving average is $0.89.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.